A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Exclusion Criteria

• •Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis).
• •History of solid organ transplantation.
• •Subprotocol C
• •Inclusion:
• •Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years).
• •Histologically or cytologically confirmed diagnosis of metastatic and/or unresectable (locally advanced) adenocarcinoma of the pancreas.
• •Homozygous MTAP-deletion.
• •Rat Sarcoma Viral Oncogene Homolog (RAS) mutation
• •Received at least 1 prior systemic therapy for advanced or metastatic PDAC.
• •Disease measurable as defined by RECIST v1.1.
• •Adequate organ function as defined in the protocol.
• •Exclusion:
• •Prior treatment with aMAT2A inhibitor, a PRMT5 inhibitor, or a MAPK pathway inhibitor, including KRAS inhibitors.
• •Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis).
• •History of solid organ transplantation.